Cancer Research Cancer Epigenetics  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Laposa, R. R.
Right arrow Articles by Cleaver, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laposa, R. R.
Right arrow Articles by Cleaver, J. E.
[Cancer Research 63, 3909-3912, July 15, 2003]
© 2003 American Association for Cancer Research


Advances in Brief

Recapitulation of the Cellular Xeroderma Pigmentosum-Variant Phenotypes Using Short Interfering RNA for DNA Polymerase H1

Rebecca R. Laposa, Luzviminda Feeney and James E. Cleaver2

Department of Dermatology and University of California San Francisco Cancer Center, University of California, San Francisco, California 94143-0808

The lesion-specific DNA polymerase POLH gene is mutated in xeroderma pigmentosum variant (XP-V) patients who exhibit an increased skin cancer incidence from UV exposure. Normal cells in which POLH expression was reduced using short interfering RNAs (siRNAs) were compared with the XP-V cellular phenotype that results from naturally occurring inactivating mutations. Stable clones expressing siRNA had partially reduced POLH protein levels, and intermediate levels of UV sensitivity and S phase checkpoint activation, but similar levels of Mre11 foci as in XP-V cells. Therefore, suppression of POLH expression levels by siRNA recapitulates most of the phenotypes seen in cells from XP-V patients with inactivating mutations in POLH.




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
Y.-w. Chen, J. E. Cleaver, Z. Hatahet, R. E. Honkanen, J.-Y. Chang, Y. Yen, and K.-m. Chou
Human DNA polymerase {eta} activity and translocation is regulated by phosphorylation
PNAS, October 28, 2008; 105(43): 16578 - 16583.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
Y.-w. Chen, J. E. Cleaver, F. Hanaoka, C.-f. Chang, and K.-m. Chou
A Novel Role of DNA Polymerase {eta} in Modulating Cellular Sensitivity to Chemotherapeutic Agents
Mol. Cancer Res., April 1, 2006; 4(4): 257 - 265.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
G. Liu and X. Chen
DNA Polymerase {eta}, the Product of the Xeroderma Pigmentosum Variant Gene and a Target of p53, Modulates the DNA Damage Checkpoint and p53 Activation
Mol. Cell. Biol., February 15, 2006; 26(4): 1398 - 1413.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
D. S.F. Biard, E. Despras, A. Sarasin, and J. F. Angulo
Development of New EBV-Based Vectors for Stable Expression of Small Interfering RNA to Mimick Human Syndromes: Application to NER Gene Silencing
Mol. Cancer Res., September 1, 2005; 3(9): 519 - 529.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.